Research Topics
| Richard Ac HughesSummaryAffiliation: King's College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathyRichard A C Hughes
Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
J Peripher Nerv Syst 11:30-46. 2006..Corticosteroids, intravenous immunoglobulin and plasma exchange each provide short term benefit but the possible long-term benefits of immunosuppressive drugs have yet to be confirmed in randomised, controlled trials...
Peripheral neuropathyRichard A C Hughes
Department of Neuroimmunology, Guy's Campus, Guy's, King's, and St Thomas's School of Medicine, London SE1 1UL
BMJ 324:466-9. 2002
Guillain-Barré syndromeRichard A C Hughes
Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Hospital, UK
Lancet 366:1653-66. 2005..Further research is needed to discover treatments to prevent 20% of patients from being left with persistent and significant disability...
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the PeripherR A C Hughes
King s College London School of Medicine, London, UK
Eur J Neurol 13:326-32. 2006....
No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000Richard A Hughes
Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Campus, London, England
Arch Intern Med 166:1301-4. 2006..Our goal was to determine whether immunization is associated with the incidence of Guillain-Barré syndrome (GBS)...
Immunotherapy for Guillain-Barré syndrome: a systematic reviewRichard A C Hughes
Department of Clinical Neuroscience, King s College London, Guy s Campus, London, UK
Brain 130:2245-57. 2007..Since approximately 20% of patients die or have persistent disability despite immunotherapy, more research is needed to identify better treatment regimens and new therapeutic strategies...
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trialRichard A C Hughes
Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
Lancet Neurol 7:136-44. 2008..We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP...
Treating nerves: a call to armsRichard A C Hughes
Department of Clinical Neuroscience, King s College London, London, UK
J Peripher Nerv Syst 13:105-11. 2008..The Peripheral Nerve Society has formed a standing committee, the Inflammatory Neuropathy Consortium (http://pns.ucsd.edu/INC.htm), to facilitate the trials needed to answer the remaining questions in the inflammatory neuropathies...
Advances in the use of IVIg in neurological disordersRichard Hughes
Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King's College London, Guy's Hospital, London, SE1 1UL, UK
J Neurol 255:1-2. 2008
The role of IVIg in autoimmune neuropathies: the latest evidenceRichard Hughes
Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, SE1 1UL, UK
J Neurol 255:7-11. 2008..011). On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP. For MMN, although the evidence for IVIg is limited, there is no evidence to recommend other treatments...
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trialRichard A C Hughes
Department of Clinical Neuroscience, Institute of Psychiatry, King s College London, London SE5 8AF, UK
Expert Rev Neurother 9:789-95. 2009..Adverse events were mostly mild and serious adverse events were not more common with IVIg than with placebo. The results persuaded the US FDA and Health Canada to approve Gamunex for use in CIDP...
Supportive care for patients with Guillain-Barré syndromeRichard A C Hughes
Department of Clinical Neuroscience, King s College, London, England
Arch Neurol 62:1194-8. 2005..More research is needed to identify optimal methods for all aspects of supportive care...
Campylobacter jejuni in Guillain-Barré syndromeRichard Hughes
Department of Clinical Neurosciences, Guy's King's and St Thomas School of Medicine, King's College, London, UK
Lancet Neurol 3:644. 2004
Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit?Richard A C Hughes
Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, SE1 1 UL, London, UK
Lancet 363:181-2. 2004
Interferon beta 1a for secondary progressive multiple sclerosisRichard A C Hughes
Department of Neuroimmunology, Guy s, King s and St Thomas School of Medicine, Guy s Hospital, London SE1 1 UL, UK
J Neurol Sci 206:199-202. 2003..These conclusions should be reviewed when the full results of all four trials have been published...
A controlled investigation of the cause of chronic idiopathic axonal polyneuropathyR A C Hughes
Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, London SE1 1UL, UK
Brain 127:1723-30. 2004..A logistic regression analysis identified environmental toxin exposure and hypertriglyceridaemia, but not glucose intolerance or alcohol overuse as significant risk factors that deserve further investigation as possible causes of CIAP...
Management of chronic inflammatory demyelinating polyradiculoneuropathyRichard A C Hughes
Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, London, UK
Drugs 63:275-87. 2003..General measures to rehabilitate patients and manage symptoms, including foot drop, weak hands, fatigue and pain, are important...
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyMohamed Mahdi-Rogers
Department of Neurology, King s College Hospital, Denmark Hill, London, UK, SE5 9RS
Cochrane Database Syst Rev 11:CD003280. 2010..It is probably due to an autoimmune process. Immunosuppressive or immunomodulatory drugs would be expected to be beneficial...
Corticosteroids for Guillain-Barré syndromeRichard Ac Hughes
MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, PO Box 114, Queen Square, London, UK, WC1N 1BG
Cochrane Database Syst Rev 2:CD001446. 2010..According to low quality evidence oral corticosteroids delay recovery. Diabetes requiring insulin was significantly more and hypertension less common with corticosteroids...
Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathyPaul McCrone
Centre for the Economics of Mental Health, Health Services Research Department, Institute of Psychiatry, King s College London, UK
Eur J Neurol 10:687-94. 2003..The impact of later side-effects of prednisolone on long-term costs and quality of life are likely to reduce the cost per QALY of IVIg treatment...
Systematic reviews to help guide clinical practice in neuromuscular diseaseKate Jewitt
Cochrane Neuromuscular Disease Group, Department of Neuroimmunology, Guy's, King's and St Thomas' School of Medicine, Guy's Campus, London, UK
J Neurol Neurosurg Psychiatry 74:ii43-ii44. 2003
Intravenous immunoglobulin for Guillain-Barré syndromeRichard A C Hughes
MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK
Cochrane Database Syst Rev 7:CD002063. 2012..Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective...
Corticosteroids for Guillain-Barré syndromeRichard A C Hughes
MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK
Cochrane Database Syst Rev 8:CD001446. 2012..Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit...
Brain-derived neurotrophic factor in experimental autoimmune neuritisPaul A Felts
Department of Neuroimmunology and the Neuroinflammation Research Group, Guy s, King s and St Thomas School of Medicine, King s College London, Guy s Campus, London SE1 1UL, UK
J Neuroimmunol 124:62-9. 2002..With the exception of a possibly protective effect indicated by bladder weight, this study suggests that BDNF may not provide an effective therapy for GBS, at least in the acute phase of the disease...
A clinical prognostic scoring system for Guillain-Barré syndromeRinske van Koningsveld
Department of Neurology, Erasmus MC, Rotterdam, Netherlands
Lancet Neurol 6:589-94. 2007..We aimed to develop and validate a scoring system based on clinical characteristics in the acute phase of GBS to predict outcome at 6 months...
Management of inflammatory neuropathiesRobert D M Hadden
West London Neurosciences Centre, Charing Cross Hospital, London, UK
J Neurol Neurosurg Psychiatry 74:ii9-ii14. 2003
Increased incidence of carpal tunnel syndrome up to 10 years before diagnosis of diabetesMartin C Gulliford
Division of Health and Social Care Research, King's College, London, UK
Diabetes Care 29:1929-30. 2006
Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathyDavid Allen
Department of Clinical Neurosciences, Guy s Campus, Guy s, King s and St Thomas School of Medicine, King s College, Denmark Hill, London SE5 9RS, UK
J Peripher Nerv Syst 10:174-80. 2005..Six CIDP and seven GBS patients' sera reacted with this band. These results support the view that antibodies to myelin proteins, and especially P0, are present in the serum of some patients with CIDP and GBS...
Guillain-Barré syndromeJane Pritchard
Department of Clinical Neurosciences, Guy's Hospital, Guy's, King's and St Thomas' School of Medicine, London SE1 1UL, UK
Lancet 363:2186-8. 2004
Cochrane systematic reviews of treatments for peripheral nerve disordersRichard A C Hughes
J Peripher Nerv Syst 9:127-9. 2004
Anti-myelin-associated glycoprotein antibodies alter neurofilament spacingMichael P T Lunn
Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Brain 125:904-11. 2002..8+/-4.6 nm). This reinforces the hypothesis that MAG is involved in the control of neurofilament spacing through sidearm phosphorylation and demonstrates a MAG-mediated pathogenic effect of the anti-MAG antibody in peripheral nerves...
Reduced circulating CD4+CD25+ cell populations in Guillain-Barré syndromeJane Pritchard
Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Campus, London SE1 1UL, UK
J Neuroimmunol 183:232-8. 2007..4%, 95% CI 1.1-1.8%, p=0.005. Since CD4+CD25+ cells include cells with special immunoregulatory functions, further investigation of this phenomenon and its relation to possible loss of regulatory T cell function in GBS is warranted...
Treating nerves: from anecdote to systematic reviewRichard A C Hughes
Department of Clinical Neurosciences, Guy's, King's and St Thomas' School of Medicine, London SE1 1UL, UK
J R Soc Med 96:432-5. 2003
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphismsNina M van Sorge
Department of Neurology G03 228, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
J Neuroimmunol 162:157-64. 2005..Results suggest that Fc gammaRIII genotypes may represent mild disease-modifying factors in GBS...
